Prognostic index expression of cyclin-D1, cerbB-2 and VEGF: Metastases vs corresponding primary cancers and metastatic vs non-metastatic adenocarcinomas

Histology and Histopathology

Volumn 23, Issue 8, 2008, Pages 987-993

  Parra, Edwin Roger ^a   Park, Ji Young ^a   Saito, Dalva Midori ^a   Takagaki, Teresa Yae ^a   Rodrigues, Olavo Ribeiro ^b   Capelozzi, Vera Luiza ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDADE DE MOGI DAS CRUZES   (Brazil)

Author keywords

C erbB 2; Cyclin D1; Lung cancer; Prognostic; VEGF

Indexed keywords

CYCLIN D; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BRAZIL; CANCER STAGING; FEMALE; HUMAN; LUNG TUMOR; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BRAZIL; CYCLINS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 46249115221     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Antonangelo L., Bernardi F.D.C., Capelozzi V.L., Takagaki T.Y., Younes R.N., Yagi N. and Saldiva P.H. (1997). Morphometric evaluation of argyrophilic nucleolar organizer region is useful in predicting long-t.erm survival in squamous cell carcinoma of the lung. Chest 111, 110-114.
2. Battlehner C.N., Saldiva P.H.N., Carvalho C.R.R., Takagaki T.Y., Montes G.S., Younes R.N. and Capelozzi V.L. (1993). Nuclear/ cytoplasmic ratio correlates strongly with survival in nondisseminated neuroendocrine carcinoma of the lung. Histopathology 22, 31-34.
3. Bernardi F.C., Antonângelo L., Beyruti R., Takagaki T., Saldiva P.H. and Capelozzi V.L. (1997). A prognostic model of survival in surgically resected squamous cell carcinoma of the lung using clinical, pathologic, and biologic markers. Mod. Pathol. 10, 992-1000.
4. Bernardi Fdel C., Capelozzi V.L., Takagaki T.Y., Younes R.N. and Saldiva P.H. (1995). Usefulness of morphometric evaluation of histopathological slides is useful in predicting long-term outcome of patients with squamous cell carcinoma of the lung. A preliminary report. Chest 107, 614-620.
5. Blood C.H. and Zetter B. (1990). Tumor interactions with the vasculature: angiogenesis and tumor metastases. Biochem. Biophys. Acta 1032, 89-118.
6. Capelozzi V.L., Battlehner C.N, Montes G.S. and Saldiva PH. (1993). Volume fraction of dense-core granules correlates well with survival in disseminated (Stage IV) neuroendocrine carcinoma of the lung. Pathol. Pract. Res. 189, 1145-1148.
7. Caporrino C., Saldiva P.H., Farhat C.A., Takagaki T.Y., Younes R.N. and Capelozzi V.L. (1999). Stereological estimates of nuclear star volume and vessels as predictors of chemotherapy response in small cell carcinoma of the lung. Histopathology 35, 257-266.
8. Carvalho H.A., Saldiva P.H., Takagaki T.Y. and Capelozzi V.L. (1997). Stereological estimates of nucleus/cytoplasm ratio and star volume on fiberoptic biopsies are of prognostic value to discriminate survival after radiotherapy in advanced squamous cell carcinoma of the lung. Histopathology 31, 420-429.
9. Carvalho P.E., Antonãngelo L., Bernardi F.D., Leão L.E., Rodrigues O.R. and Capelozzi V.L. (2000). Useful prognostic panel markers to express the biological tumours status in resected lung adenocarcinomas. Jpn. J. Clin. Oncol. 30,478-486.
10. Demarchi L.M., Reis M.M., Palomino S.A., Farhat C., Takagaki T.Y., Beyruti R., Saldiva P.H. and Capelozzi V.L. (2000). Prognostic values of stromal density and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung. Mod. Pathol.13, 511-520.
11. Dragnev K.H., Stover D., Dmitrovsky E. and American College of Chest Physicians. (2003). Frequent molecular genetic changes that occur during lung carcinogenesis have been identified. Lung Cancer Prevent. 123, 605-715.
12. Folkman J. (1990). What is the evidence that tumours are angiogenesis dependent? J. Natl. Cancer Inst. 82, 4-6.
13. Gugger M., Kappeler A., Vonlanthen S., Altermatt H.J., Ris H.B., Lardinois D., Borner M.M., Heighway J. and Betticher D.C. (2001). Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours. Lung Cancer 33, 229-239.
14. Gundersen H.J.G., Bendtsen T.F., Korbo L., Marcussen N., Moller A., Nielsen K., Nyengaard J.R., Pakkenberg B., Sorensen F.B., Vesterby A. and West M.J. (1988). Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 96, 379-394.
15. Gusterson B.A., Gelber R.D., Goldhirsch A., Price K.N., Säve-Söderborgh J., Anbazhagan R., Styles J., Rudenstam C.M., Golouh R. and Reed R. (1992). Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol. 10, 1049-1056.
16. Han H., Landreneau R.J., Santucci T.S., Tung M.Y., Macherey R.S., Shackney S.E., Sturgis C.D., Raab S.S. and Silverman J.F. (2002). Prognostic value of immunohistochemical expressions of p53, HER- 2/neu, and bcl-2 in stage non-small-cell lung cancer. Human Pathol. 33, 105-110.
17. Janssen-Heijnen M.L., Gatta G., Forman D., Capocaccia R. and Coebergh J.W. (1998). Variation in survival of patients with lung cancer in Europe, 1985-1989. Eur. J. Cancer 34, 2191-2196.
18. Jimenez-Orozco F.A. (2001). Decrease of Cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin. Lung Cancer 34, 185-194.
19. Keum J.S., Kong G., Yang S.C., Shin D.H., Park S.S., Lee J.H. and Lee J.D. (1999). Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br. J. Cancer 81, 127-32.
20. Mountain C.F. (2000). The new international system for staging lung Cancer. Semim. Surg. Oncol. 18, 106-125.
21. Nishio M., Koshikawa T., Yatabe Y., Kuroishi T., Suyama M., Nagatake M., Sugiura T., Ariyoshi Y., Mitsudomi T. and Takahashi T. (1997). Prognostic significance of Cyclin D1 and retinoblastoma expression in combination of p53 abnormalities in primary, resected non-small cell lung cancers. Clin. Cancer Res. 3, 1051-1058.
22. Petty W.J., Dragnev K.H. and Dmitrovsky E. (2003). Cyclin D1 as a target for chemoprevetion. Lung Cancer 41, S155-S161.
23. Rodrigues O.R., Antonangelo L., Yagi N., Minamoto H., Schmidt Jr A.F., Capelozzi V.L., Goldenberg S. and Saldiva P.H. (1997). Prognostic significance of argyrophilic nucleolar organizer region (AgNOR) in resected non-small cell lung cancer. Jpn. J. Clin. Oncol. 27, 298-304.
24. Salomon D.S, Brandt R., Ciardiello F. and Normanno N. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Haematol. 19, 183-232.
25. Shibuya M. (2006). Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol. 39, 469-478.
26. Shinkaruk S., Bayle M., Lain G. and Deleris G. (2003). Vascularendothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr. Med. Chem. Anticancer Agents. 3, 95-117.
27. Travis W., Colby T., Corrin B., Shimosato Y., and Brambilla E. (1999). Histological typing of tumours of lung and pleural. In: World Health Organization International Classification of tumours. Sobin L.H. (ed). 3rd ed. Springer-Verlag. New York. p 156.
28. Veale D., Kerr N., Gibson G.J., Kelly P.J. and Harris A.L. (1993). The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br. J. Cancer 68, 162-165.
29. Wingo P.A., Ries L.A., Rosenberg H.M., Miller D.S. and Edwards B.K. (1998). Cancer incidence and mortality, 1973-1995: a report card for the U.S. Cancer 82, 1197-1207.
30. Younes R.N. (1997). Lung cancer: role of surgery in the treatment of non-small cell lung cancer stages I, II and III. South Am. J. Cancer 1, 153.